Todd Girolamo

Todd Girolamo was appointed to Longeveron’s Board of Directors in February 2022. Mr. Girolamo is currently General Counsel at ProKidney LP, a clinical-stage cellular therapeutics company focused on therapies for chronic kidney disease (CKD) and prevention of end-stage renal disease (ESRD) and need for dialysis. Prior to joining ProKidney, he spent 11 years as Chief Legal Officer, Senior Vice President of Corporate Development and Corporate Secretary for Caladrius Biosciences, Inc. (NASDAQ: CLBS), a regenerative medicine development company. Mr. Girolamo is a seasoned attorney specializing in therapeutic products and businesses. His experience includes SEC, Nasdaq, and clinical compliance; corporate finance; M&A; licensing; intellectual property; litigation; and drug development.

Mr. Girolamo began his legal career as a corporate law associate at Cahill Gordon & Reindel and concluded his tenure in private practice at Reid & Priest where he gained expertise as a general commercial litigator practicing in the areas of intellectual property, securities law, employment law and bankruptcy. In addition to almost two decades of experience as both corporate counsel and private practitioner, Mr. Girolamo spent 12 years on Wall Street where he specialized in therapeutic healthcare equity securities at Oppenheimer & Co., CIBC World Markets, Leerink & Company and Summer Street Research Partners as a Series 24, 7 and 63 licensed principal. Subsequently he served as an analyst and portfolio manager at Lion’s Path Capital, managing a long-short portfolio of biopharma and med-tech equities.

​

​Mr. Girolamo received a Bachelor of Arts from Harvard College, Juris Doctor from the University of Pennsylvania Law School and Master of Business Administration from Columbia Business School.